Bangkok, Thailand — 21–23 November 2024 — Genèse Labs has taken part in AMWC Southeast Asia 2024 in Bangkok, extending its international congress activity into one of the fastest-growing regions in aesthetic medicine.

Southeast Asia has emerged as an important engine of global aesthetics-market expansion, supported by rising disposable income, high social acceptance of aesthetic treatments and substantial medical tourism. Thailand in particular has established international standing as a treatment destination and maintains a practitioner community with high treatment volumes — which in turn means correspondingly high standards for product performance and consistency.

Discussions with Southeast Asian practitioners revealed clinical priorities distinct from those of the European market — an emphasis on improving skin texture and tone, treatment approaches suited to regional skin characteristics, and strong interest in biostimulation over volume augmentation. These preferences aligned precisely with Proluma™ PDLLA: improvement appearing naturally over three to four weeks without immediate volume change, combined with minimal downtime, matched the requirements of a patient base that prefers treatment to remain undetectable. Enquiries were especially frequent regarding the PDLLA 200 mg formulation, which targets early signs of ageing in patients in their thirties and forties.

AMWC Southeast Asia established the regional presence of Genèse Labs ahead of expansion across Asia. Participation in Cosmoprof Asia in Hong Kong followed the same year, leading on to activity in Vietnam, Indonesia, Korea and China — forming an Asian congress strategy anchored in the relationships that began in Bangkok.

From November 21–23, 2024, Genèse Labs proudly participated in AMWC Southeast Asia 2024 in Bangkok, Thailand — the region’s newest and most ambitious congress dedicated to aesthetic and anti-aging medicine. Held at the modern Queen Sirikit National Convention Center, the inaugural edition attracted several thousand medical professionals, hundreds of exhibitors, and a diverse international audience eager to explore emerging scientific developments and clinical technologies shaping the global aesthetic industry. For Genèse Labs, AMWC Southeast Asia represented a strategic moment to deepen its footprint in the rapidly growing Southeast Asian market, introduce its latest innovations, and reinforce its identity as a leading global provider of advanced, science-driven aesthetic solutions.

Throughout the three-day event, the Genèse Labs booth became a hub for meaningful dialogue, product exploration, and scientific exchange. Visitors had the opportunity to experience the company’s portfolio first-hand, including RG60®, the high-performance body filler designed for structural contouring, projection, and natural volume; Proluma™, the PDLLA collagen stimulator engineered to deliver gradual, long-lasting facial rejuvenation; Citrus Bottle, the refined fat-dissolving solution formulated with Lecithin, Bromelain, and Riboflavin for targeted body shaping; and Exoluma™, Genèse Labs’ newly launched dual exosome innovation featuring Human Exosomes and Plant Exosomes, offering clinics flexible regenerative solutions. Interest in Exoluma™ was particularly strong, as practitioners across Asia increasingly seek biologically advanced, high-efficacy regenerative treatments. RG60® and Proluma™ also drew significant attention for their strong clinical performance and elegant formulation balance.

AMWC Southeast Asia attracted leading dermatologists, aesthetic physicians, plastic surgeons, and distributors from Thailand, Vietnam, Malaysia, Singapore, Indonesia, the Philippines, Hong Kong, Korea, and the Middle East. For Genèse Labs, the congress served as an opportunity to strengthen relationships with current partners and regional representatives, discuss strategic collaborations and new distribution opportunities, review upcoming regulatory pathways across ASEAN markets, present the scientific and branding philosophy supporting each Genèse Labs product, and understand practitioner needs and the evolving treatment trends shaping aesthetic practice in Southeast Asia. The high engagement underscored the region’s strong appetite for premium solutions rooted in innovation, safety, and reliable cosmetic outcomes.

Genèse Labs’ presence at AMWC Southeast Asia 2024 marks a key milestone in the company’s broader international growth initiatives. With increasing recognition across Europe, Latin America, and the Middle East, the company continues to strengthen its position in Asia — one of the fastest-developing markets in aesthetic medicine. This event follows Genèse Labs’ showcases at AMWC Latin America and Cosmoprof Asia earlier in the year, reinforcing the company’s goal of becoming a trusted global partner capable of supporting clinics with scientifically refined, elegantly formulated aesthetic innovations. As the demand for regenerative and performance-based treatments expands, Genèse Labs remains committed to advancing its research, enhancing product availability, and supporting practitioners with reliable, high-quality solutions.

Genèse Labs is a Paris-founded aesthetic company dedicated to science-based, regulatory-led product development across the fast-growing fields of body contouring, collagen biostimulation, and regenerative skincare. Since its foundation in 2019, the company has built its portfolio — including RG60®, Proluma™, Citrus Bottle™ and the Exoluma™ series — on three principles: scientifically verifiable formulations, regulatory compliance in every market entered, and continuous engagement with the international clinical and academic community. Genèse Labs partners with dermatologists, aesthetic physicians, and distributors worldwide to advance the standard of modern aesthetic medicine. For more information: www.geneselabs.net.